tetano
Editor, Senior Moderator
Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique, Spain, January and February 2021
Mar?a Fern?ndez-Prada[SUP]1,2[/SUP] , Irene Rivero-Calle[SUP]2,3,4[/SUP] , Ana Calvache-Gonz?lez[SUP]5[/SUP] , Federico Martin?n-Torres[SUP]2,3,4[/SUP]
Monitoring adverse reactions following immunisation is essential, particularly for new vaccines such as those against COVID-19. We describe 20 cases of acute onset of a single supraclavicular lymphadenopathy manifesting between 24 h and 9 days after ipsilateral intramuscular administration of an mRNA-based COVID-19 vaccine, referred to our WHO Collaborating Centre for Vaccine Safety. Our results indicate that the swelling of supraclavicular lymph nodes following immunisation may constitute a benign and self-limited condition, related to a higher than recommended injection site.
[SUP]full article[/SUP]
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.10.2100193
Mar?a Fern?ndez-Prada[SUP]1,2[/SUP] , Irene Rivero-Calle[SUP]2,3,4[/SUP] , Ana Calvache-Gonz?lez[SUP]5[/SUP] , Federico Martin?n-Torres[SUP]2,3,4[/SUP]
Monitoring adverse reactions following immunisation is essential, particularly for new vaccines such as those against COVID-19. We describe 20 cases of acute onset of a single supraclavicular lymphadenopathy manifesting between 24 h and 9 days after ipsilateral intramuscular administration of an mRNA-based COVID-19 vaccine, referred to our WHO Collaborating Centre for Vaccine Safety. Our results indicate that the swelling of supraclavicular lymph nodes following immunisation may constitute a benign and self-limited condition, related to a higher than recommended injection site.
[SUP]full article[/SUP]
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.10.2100193